January 11, 2024 02:11 PM EST
Pharma

Bio­gen ends agree­ment with Acor­da for mul­ti­ple scle­ro­sis drug Fampyra

Katherine Lewin

News Reporter

Bio­gen is hand­ing back ex-US com­mer­cial­iza­tion rights to Acor­da Ther­a­peu­tics for the mul­ti­ple scle­ro­sis drug Fampyra.

Acor­da will have the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

A service from the Financial Times